120 related articles for article (PubMed ID: 36876696)
21. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
22. Correlation between PET/CT parameters and KRAS expression in colorectal cancer.
Chen SW; Chiang HC; Chen WT; Hsieh TC; Yen KY; Chiang SF; Kao CH
Clin Nucl Med; 2014 Aug; 39(8):685-9. PubMed ID: 24978328
[TBL] [Abstract][Full Text] [Related]
23. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by
Ikeno Y; Seo S; Iwaisako K; Yoh T; Nakamoto Y; Fuji H; Taura K; Okajima H; Kaido T; Sakaguchi S; Uemoto S
J Transl Med; 2018 Apr; 16(1):95. PubMed ID: 29642912
[TBL] [Abstract][Full Text] [Related]
24. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
25. Predictive Value of Metabolic Parameters Derived From
Liu H; Ye Z; Yang T; Xie H; Duan T; Li M; Wu M; Song B
Front Immunol; 2021; 12():724464. PubMed ID: 34512653
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of FDG-PET and DWI in breast cancer.
Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
Ann Nucl Med; 2018 Jan; 32(1):44-53. PubMed ID: 29134565
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
28. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance and Prognostic Value of the Maximum Standardized Uptake Value of
Yin YX; Xie MZ; Liang XQ; Ye ML; Li JL; Hu BL
Front Oncol; 2021; 11():741612. PubMed ID: 34956868
[TBL] [Abstract][Full Text] [Related]
30. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
31. Baseline [
Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
[TBL] [Abstract][Full Text] [Related]
32. The Evaluation of Preoperative
Vural Topuz Ö; Aksu A; Erinç SR; Tokgözoğlu N; Tamam MÖ
Mol Imaging Radionucl Ther; 2022 Feb; 31(1):16-22. PubMed ID: 35114747
[TBL] [Abstract][Full Text] [Related]
33. Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters.
Lee H; Chung YS; Lee JH; Lee KY; Hwang KH
World J Clin Cases; 2022 Jan; 10(1):155-165. PubMed ID: 35071515
[TBL] [Abstract][Full Text] [Related]
34. Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer.
Lee SS; Choi SJ; Park JS
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3501-3506. PubMed ID: 36308376
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Mediastinal Tumors Using SUV
Morita T; Tatsumi M; Ishibashi M; Isohashi K; Kato H; Honda O; Shimosegawa E; Tomiyama N; Hatazawa J
Asia Ocean J Nucl Med Biol; 2017; 5(1):22-29. PubMed ID: 28840135
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
37. The role of
Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of baseline
Reyes Marlés RH; Navarro Fernández JL; Puertas García-Sandoval JP; Santonja Medina F; Mohamed Salem L; Frutos Esteban L; Contreras Gutiérrez JF; Castellón Sánchez MI; Ruiz Merino G; Claver Valderas MA
Eur J Hybrid Imaging; 2021 Sep; 5(1):16. PubMed ID: 34476632
[TBL] [Abstract][Full Text] [Related]
39. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
40. The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer.
Eryilmaz A; Cengiz A; Basal Y; Meteoglu I; Omurlu IK; Yurekli Y
J Cancer Res Ther; 2018; 14(5):994-998. PubMed ID: 30197337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]